Cantor Fitzgerald Starts CytomX Therapeutics (CTMX) at Overweight
Tweet
Share
E-mailGet Alerts CTMX Hot Sheet
Price: $2.70 -1.82%
Rating Summary:
14 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Rating Summary:
14 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Join SI Premium – FREE
Cantor Fitzgerald initiates coverage on CytomX Therapeutics (NASDAQ: CTMX) with a Overweight rating and a price target of $35.00.
Analyst Mara Goldstein sees potential for the company to create a best-in-class pipeline among bio-therapeutic companies.
For an analyst ratings summary and ratings history on CytomX Therapeutics click here. For more ratings news on CytomX Therapeutics click here.
Shares of CytomX Therapeutics closed at $20.04 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kotak Starts Dhoot Transmission (DHOOTTRA:IN) at Sell (4)
- Costco Wholesale (COST) PT Raised to $1,040 at DA Davidson Following Q4 Earnings
- Costco Wholesale (COST) PT Lowered to $1,010 at Freedom Broker
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
Cantor Fitzgerald, Mara GoldsteinSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
